Markets · delayed Markets · delayed · loading…
← Back to all news
Science AfricaBriefHealth Checked story Published 18 November 2026 · Updated 18 Nov, 14:45 UTC

Gilead signs royalty-free generic licensing deals for its experimental Ebola drug in 127 countries

Gilead Sciences said on Monday it has signed royalty-free voluntary licensing agreements with three generic manufacturers — Dr. Reddy's Laboratories, Eva Pharma and Ferozsons Laboratories — to support future access to obeldesivir, its experimental antiviral being tested as post-exposure prevention for Ebola Bundibugyo virus disease. The deals cover 127 mainly low- and lower-middle-income countries, including every African country that has reported cases in the current outbreak. The drug is not approved anywhere, and a Phase 3 trial is still under way.

A health worker preparing to enter an Ebola treatment unit (file photo)
Photo: CDC Global via Wikimedia Commons (CC BY 2.0) · (File photo — not from this event)

Key points

  • Three generic makers — Dr. Reddy's, Eva Pharma and Ferozsons — can prepare to make obeldesivir royalty-free in 127 countries.
  • The territory includes every African country reporting cases in the current Ebola Bundibugyo outbreak.
  • Obeldesivir is experimental: a Phase 3 post-exposure trial is still running and it is approved nowhere.
Show more (1)
  • Gilead is also extending its remdesivir licences to filovirus disease, conditional on trial results and approvals.
Your take
Sign in to record your take — it’s free, so one person counts once
Takes sit on a free account, so one person counts once.

What happened

The current Ebola outbreak, driven by the Bundibugyo species, was announced in DR Congo in mid-May and has become the country's largest, with cases also reported in other African countries. There is no approved vaccine or specific treatment for the Bundibugyo virus, which is why prevention after exposure is being tested in the field.

Licensing generic makers before a drug is approved is meant to shorten the gap between a successful trial and affordable supply in the countries where the disease occurs.

What we know / what we don't know yet

What we know

  • The three licensees, the royalty-free terms and the 127-country scope, from Gilead's own announcement.
  • That obeldesivir is unapproved everywhere and still in a Phase 3 post-exposure trial.

What we don't know yet

  • Whether the EBO-PEP trial shows obeldesivir prevents Ebola Bundibugyo disease — no results have been announced.
  • Whether regulators approve the drug, and when generic supply could reach patients if they do.
§

Claim by claim

4 verified· 0 disputed· 0 not yet verified· 0 corrected
Show all claims (4)
Verified
Gilead Sciences has signed royalty-free voluntary licensing agreements with three generic manufacturers — Dr. Reddy's Laboratories, Eva Pharma and Ferozsons Laboratories — for its investigational antiviral obeldesivir. The agreements cover 127 primarily low- and lower-middle-income countries, including all African countries that have reported cases during the current Ebola Bundibugyo outbreak.

Why this label: The agreements, the three manufacturers and the 127-country scope are set out in Gilead's own announcement; Reuters' report of the deals agrees.

On the ladder: a claim earns Verified from primary evidence, or from two independent sources that do not copy each other.

Verified
Obeldesivir is being tested as post-exposure prophylaxis for Ebola Bundibugyo virus disease in the EBO-PEP trial, a Phase 3 randomised, placebo-controlled field trial coordinated by ALIMA and partners among people at high risk of developing the disease after exposure. The drug has shown activity against several Ebola-related viruses in preclinical studies but is not approved for any use in any country.

Why this label: The trial's design and the drug's unapproved status are stated in Gilead's announcement and in Reuters' report; no efficacy result has been announced.

On the ladder: a claim earns Verified from primary evidence, or from two independent sources that do not copy each other.

Verified
The agreements are intended to support manufacturing readiness, technology transfer and supply planning before the trial results and any regulatory filings. Technology transfer discussions are already under way, and agreements with additional manufacturers are under discussion.

Why this label: The purpose and the state of the technology-transfer talks are Gilead's own account in its announcement.

On the ladder: a claim earns Verified from primary evidence, or from two independent sources that do not copy each other.

Verified
Gilead is also updating its existing voluntary licensing agreements for remdesivir to include filovirus disease, supporting potential future access if the WHO-sponsored PARTNERS trial supports remdesivir's use as a treatment for Ebola Bundibugyo disease and regulators approve it.

Why this label: The remdesivir licence update and its conditions are stated in Gilead's announcement; the PARTNERS trial has not reported.

On the ladder: a claim earns Verified from primary evidence, or from two independent sources that do not copy each other.

Why it matters

If obeldesivir works, the deals decide how fast and how cheaply it can reach the African countries fighting this outbreak — the manufacturing and supply groundwork is being laid now, before anyone knows whether the drug succeeds.

Background

  • The Ebola Bundibugyo outbreak was announced in DR Congo; it has become the country's largest Ebola outbreak.

  • Gilead signed royalty-free licensing deals with three generic manufacturers for obeldesivir, covering 127 countries.

Update history

No silent edits. Every change is written here, with its time.

  • Latest

    Published — the deals are confirmed against Gilead's own announcement, with Reuters reporting them in the same terms.

← Back to all news